Ronen Twito, Executive Chairman and Chief Executive Officer of Kadimastem & Alexander Zwyer, Chief Executive Officer of NLS Pharmaceutics: NewCelX- Israel Science. Nasdaq Execution. Global Vision. "The AEX-6xx program significantly extends the translational scope of the DOXA platform," said Dr. Eric Konofal, Founder and Chief Scientific Officer at Aexon Labs and NLS. "We are encouraged by the robust behavioral and cellular data and are preparing for investigational new drug (IND)-enabling studies with stron ...